Details of the Drug Combinations

General Information of This Drug (ID: DM7EVUF)

Drug Name

Asciminib DM7EVUF

Synonyms

ABL-001; 1492952-76-7; Asciminib free base; ABL001-NX; UNII-L1F3R18W77; L1F3R18W77; NVP-ABL001; (R)-N-(4-(Chlorodifluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; 1492952-76-7 (free base); N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide; Asciminib [USAN]; Asciminib (ABL001); Asciminib (USAN/INN); GTPL8962; CHEMBL4208229; SCHEMBL15388306; TQP0925; EX-A3030; BDBM50459091; NSC789925; s8555; ZINC150275965; CCG-269232; CS-7655; DB12597; NSC-789925; SB18878; BS-15538; HY-104010; D11403; Q27074535; (R)-N-(4-(Chloro difluoromethoxy)phenyl)-6-(3-hydroxypyrrolidin-1-yl)-5-(1H-pyrazol-5-yl)nicotinamide; AY7

Indication

Disease Entry	ICD 11	Status	REF
Chronic myeloid leukaemia	2A20	Approved	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

5 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABL001 + Nilotinib	DC1WI5A	Nilotinib	Chronic Myelogenous Leukemia	[2]
ABL001 + Imatinib	DCGV3AT	Imatinib	Chronic Myelogenous Leukemia	[2]
ABL001 + Dasatinib	DCS6LC8	Dasatinib	Chronic Myelogenous Leukemia	[2]
ABL001 + Imatinib	DCRK7IB	Imatinib	Chronic Phase Chronic Myelogenous Leukemia	[3]
ABL001 + ABL001	DCMPJLB	ABL001	Chronic Myelogenous Leukemia	[4]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215358.
2	ClinicalTrials.gov (NCT02081378) A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
3	ClinicalTrials.gov (NCT04838041) Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
4	ClinicalTrials.gov (NCT04948333) Asciminib Treatment Optimization in ?3rd Line CML-CP.